Charles River Discovery Services offers validated human tumor xenografts, primary tumor, syngeneic, drug resistant, and specialty models in support of your drug development program. Through our broad range of service offerings and scientific expertise, our discovery team works with you to choose the most appropriate study design and screening method for an investigational agent. Depending on client needs, tumor growth delay (TGD), tumor growth inhibition (TGI), survival, combination or adjuvant design approaches may be used. Studies can be designed to:
- Identify leads
- Optimize dose schedules
- Identify optimal combination strategies
- Evaluate drug resistance/sensitivity patterns
|
|
|
Oncology, oncology models, cancer, cancer research, tumor growth delay, TGD, tumor growth inhibition, TGI, combination therapy
Oncology Models | Charles River Discovery Services
We have hundreds of in vitro/in vivo cell lines to support your oncology drug discovery program, including validated human tumor grafts, syngeneic, drug-resistant and specialty models.